China News Service, Beijing, March 9 (Wei Xianghui) Biomedicine is a strategic emerging industry related to the national economy, people's livelihood and national security.
At this year's National People's Congress, "innovative drugs" appeared in the government work report for the first time, sparking heated discussion.
Innovative drugs refer to drugs with independent intellectual property patents. Compared with generic drugs, they are of great significance to building an innovative country and can reduce dependence on foreign new drugs.
In the past, government work reports mostly described medical innovation in terms of "biomedicine" and "new drugs". However, this year's government work report clearly mentioned that we will accelerate the development of cutting-edge emerging hydrogen energy, new materials, innovative drugs and other industries, and actively create bio-manufacturing. , commercial aerospace, low-altitude economy and other new growth engines.
From "new drugs" to "innovative drugs", China's biopharmaceutical industry has entered the fast lane of high-quality development and is accelerating the formation of "new quality productivity".
Data map: Photo by China News Service reporter Jiang Qiming at the Boao Lecheng Never-Ending International Innovative Pharmaceutical Equipment Exhibition
During this year’s National Two Sessions, many representatives from the pharmaceutical industry offered suggestions and suggestions on the development of innovative drugs.
Hao Haiping, a member of the National Committee of the Chinese People's Political Consultative Conference, said that the field of biomedicine or general health is a typical new productivity.
How to promote the intelligentization, digitalization and greening of biomedicine in the next step should be an important mission and responsibility shouldered by committee members in the medical and health field.
On March 4, at the first "Committee Channel" collective interview event, Wu Beili, a member of the National Committee of the Chinese People's Political Consultative Conference and a researcher at the Shanghai Institute of Materia Medica, Chinese Academy of Sciences, said that the speed of innovative drugs entering medical insurance has accelerated significantly, and more than 80% of innovative drugs can be sold after being launched on the market. Be included in medical insurance within two years.
Indeed, for ordinary people, innovative drugs, as the main solution for many major diseases, are both available and affordable.
On the eve of the National People's Congress and the Chinese People's Political Consultative Conference, Zhang Ke, the new director of the National Medical Insurance Administration, visited Peking University People's Hospital and said, "(Public use of drugs) is not necessarily the more expensive, the best is the best solution."
Among the 100 countries negotiating for drug renewal in 2023, about 70% will renew their contracts at the original price, and the average price reduction for the other 31 price-reduced drugs will be only 6.7%.
The average price reduction for the 23 newly negotiated innovative drugs in 2023 will be 4.4 percentage points lower than the overall level of negotiations.
Wang Jun, president of Peking University People's Hospital, said that after domestic innovative drugs enter the medical insurance, doctors can promptly prescribe more precise treatment drugs to patients, making high-quality drugs available and affordable to the public, which reflects the benefits of medical insurance to the people.
Promoting high-quality development of the biopharmaceutical industry and accelerating the formation of new quality productivity of innovative drugs are inseparable from financial support.
In order to provide funds for the cultivation of emerging industries and future industries, the government work report also encourages the development of venture capital and equity investment, and optimizes the functions of industrial investment funds.
Li Chuyuan, a deputy to the National People's Congress, specifically put forward suggestions in this year's proposals to promote the development of biomedical digital economy in terms of developing new productivity and medical technology innovation.
He suggested that we should combine the characteristics of the industry to formulate laws and regulations in the field of biomedical and health digital economy, and build a fiscal, taxation and financial policy system that effectively supports the digitalization of the biomedical and health industry, reduce the cost of digital transformation of enterprises, and at the same time promote close cooperation between R&D and application, focusing on creating A group of national biopharmaceutical digital transformation demonstration enterprises.
Where there are opportunities, there are challenges. While the innovative pharmaceutical industry is accelerating its development, the industry is also accelerating reshuffling, which may usher in a reshaping of the landscape.
How to take advantage of the situation, give full play to the advantages of policy combination, and improve the industrial innovation ecology will be problems that the biopharmaceutical industry in the new era needs to solve in the future.
(over)